Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.45
NEPT's Cash to Debt is ranked lower than
87% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NEPT: 0.45 )
Ranked among companies with meaningful Cash to Debt only.
NEPT' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.77 Max: No Debt
Current: 0.45
Equity to Asset 0.55
NEPT's Equity to Asset is ranked lower than
65% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NEPT: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
NEPT' s Equity to Asset Range Over the Past 10 Years
Min: -0.42  Med: 0.54 Max: 0.83
Current: 0.55
-0.42
0.83
F-Score: 4
Z-Score: 0.22
M-Score: -0.27
WACC vs ROIC
5.56%
-11.44%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -25.45
NEPT's Operating margin (%) is ranked higher than
62% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NEPT: -25.45 )
Ranked among companies with meaningful Operating margin (%) only.
NEPT' s Operating margin (%) Range Over the Past 10 Years
Min: -262.75  Med: -40.6 Max: -9.17
Current: -25.45
-262.75
-9.17
Net-margin (%) -16.08
NEPT's Net-margin (%) is ranked higher than
65% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NEPT: -16.08 )
Ranked among companies with meaningful Net-margin (%) only.
NEPT' s Net-margin (%) Range Over the Past 10 Years
Min: -185.54  Med: -33.01 Max: -10.08
Current: -16.08
-185.54
-10.08
ROE (%) -11.97
NEPT's ROE (%) is ranked higher than
66% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NEPT: -11.97 )
Ranked among companies with meaningful ROE (%) only.
NEPT' s ROE (%) Range Over the Past 10 Years
Min: -60.55  Med: -31.3 Max: -9.66
Current: -11.97
-60.55
-9.66
ROA (%) -6.44
NEPT's ROA (%) is ranked higher than
71% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NEPT: -6.44 )
Ranked among companies with meaningful ROA (%) only.
NEPT' s ROA (%) Range Over the Past 10 Years
Min: -34.21  Med: -19.61 Max: -5.71
Current: -6.44
-34.21
-5.71
ROC (Joel Greenblatt) (%) -14.75
NEPT's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NEPT: -14.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NEPT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -80.32  Med: -32.5 Max: -10.19
Current: -14.75
-80.32
-10.19
Revenue Growth (3Y)(%) -14.60
NEPT's Revenue Growth (3Y)(%) is ranked lower than
70% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NEPT: -14.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NEPT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -17.4 Max: 30.5
Current: -14.6
0
30.5
EBITDA Growth (3Y)(%) -30.10
NEPT's EBITDA Growth (3Y)(%) is ranked lower than
82% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NEPT: -30.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NEPT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -14.5 Max: 219.3
Current: -30.1
0
219.3
EPS Growth (3Y)(%) -31.40
NEPT's EPS Growth (3Y)(%) is ranked lower than
80% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NEPT: -31.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NEPT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -20.7 Max: 200
Current: -31.4
0
200
» NEPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2014

NEPT Guru Trades in Q3 2014

Jim Simons 42,300 sh (+3.42%)
» More
Q4 2014

NEPT Guru Trades in Q4 2014

Jim Simons 53,800 sh (+27.19%)
» More
Q1 2015

NEPT Guru Trades in Q1 2015

Jim Simons 27,713 sh (-48.49%)
» More
Q2 2015

NEPT Guru Trades in Q2 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NEPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 3741
Compare:NAS:AFMD, NAS:ADMA, NAS:TCON, NAS:LIFE, NAS:ANTH, NAS:PPHM, NAS:ALDX, OTCPK:NURPF, NAS:ORMP, OTCPK:THCBF, OTCPK:CNBX, OTCPK:CWBR, AMEX:CRMD, NAS:CATB, NAS:CALA, NAS:BUR, OTCPK:BCDA, OTCPK:RCAR, NAS:SBBP, OTCPK:MCUJF » details
Traded in other countries:NEPT.Canada, NTU.Germany,
Neptune Technologies & Bioressources Inc is a biotechnology company. The Company is engaged in the development, manufacture and commercialization of marine‐derived omega‐3 polyunsaturated fatty acids.

Neptune Technologies & Bioressources Inc was incorporated on October 9, 1998. It is a biotechnology company engaged in the development, manufacture and commercialization of marine derived omega polyunsaturated fatty acids. It is engaged in the research, development and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries. The Company has three segments structured in three distinctive legal entities: the first is producing and commercializing nutraceutical products (Neptune); development and commercialization of pharmaceutical products for cardiovascular diseases applications (Acasti); and development and commercialization of pharmaceutical products for neurological diseases applications (NeuroBioPharm). The Company produces omega 3 PUFAs through its patented process of extracting oils from Antartic krill, which omega 3 PUFAs are then sold as bulk oil to company's distributors who commercialize them under their private label in the U.S., European and Australian nutraceutical markets. Its products include Neptune Krill Oil and ECOKRILL Oil generally come in capsule form and serves as a dietary supplement to consumers.

Ratios

vs
industry
vs
history
Forward P/E 10.10
NEPT's Forward P/E is ranked higher than
80% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. NEPT: 10.10 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.90
NEPT's P/B is ranked higher than
72% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. NEPT: 1.90 )
Ranked among companies with meaningful P/B only.
NEPT' s P/B Range Over the Past 10 Years
Min: 1.82  Med: 5.78 Max: 37.8
Current: 1.9
1.82
37.8
P/S 2.66
NEPT's P/S is ranked higher than
81% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. NEPT: 2.66 )
Ranked among companies with meaningful P/S only.
NEPT' s P/S Range Over the Past 10 Years
Min: 1.56  Med: 8.47 Max: 33.87
Current: 2.66
1.56
33.87
Current Ratio 2.34
NEPT's Current Ratio is ranked lower than
70% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. NEPT: 2.34 )
Ranked among companies with meaningful Current Ratio only.
NEPT' s Current Ratio Range Over the Past 10 Years
Min: 0.4  Med: 2.69 Max: 5.93
Current: 2.34
0.4
5.93
Quick Ratio 1.34
NEPT's Quick Ratio is ranked lower than
79% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. NEPT: 1.34 )
Ranked among companies with meaningful Quick Ratio only.
NEPT' s Quick Ratio Range Over the Past 10 Years
Min: 0.2  Med: 2.03 Max: 4.87
Current: 1.34
0.2
4.87
Days Inventory 202.78
NEPT's Days Inventory is ranked lower than
70% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. NEPT: 202.78 )
Ranked among companies with meaningful Days Inventory only.
NEPT' s Days Inventory Range Over the Past 10 Years
Min: 72.09  Med: 213.26 Max: 318.25
Current: 202.78
72.09
318.25
Days Sales Outstanding 70.60
NEPT's Days Sales Outstanding is ranked lower than
58% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. NEPT: 70.60 )
Ranked among companies with meaningful Days Sales Outstanding only.
NEPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.6  Med: 118.29 Max: 159.39
Current: 70.6
70.6
159.39

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.10
NEPT's 3-Year Average Share Buyback Ratio is ranked higher than
56% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. NEPT: -9.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NEPT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -30.5  Med: -14.3 Max: -2.5
Current: -9.1
-30.5
-2.5

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.63
NEPT's Price/Tangible Book is ranked higher than
69% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. NEPT: 2.63 )
Ranked among companies with meaningful Price/Tangible Book only.
NEPT' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.38  Med: 6.99 Max: 40.59
Current: 2.63
2.38
40.59
Price/Median PS Value 0.32
NEPT's Price/Median PS Value is ranked higher than
88% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. NEPT: 0.32 )
Ranked among companies with meaningful Price/Median PS Value only.
NEPT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 0.94 Max: 12
Current: 0.32
0.12
12
Earnings Yield (Greenblatt) (%) -7.34
NEPT's Earnings Yield (Greenblatt) (%) is ranked higher than
54% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. NEPT: -7.34 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NEPT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -7.4  Med: 0.35 Max: 1.1
Current: -7.34
-7.4
1.1

More Statistics

Revenue (TTM) (Mil) $29.04
EPS (TTM) $ -0.05
Beta0.06
Short Percentage of Float2.23%
52-Week Range $0.86 - 1.53
Shares Outstanding (Mil)77.95

Analyst Estimate

Feb17 Feb18
Revenue (Mil $) 37 43
EPS ($) 0.02 0.10
EPS w/o NRI ($) 0.02 0.10
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NEPT

Headlines

Articles On GuruFocus.com
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

More From Other Websites
Validity of Neptune’s Patent Upheld by Australian Patent Office / Third Challenge by Enzymotec... Nov 08 2016
Neptune Announces Stock Ticker Symbol Change to NEPT on the TSX Nov 08 2016
Validity of Neptune's Patent Upheld by Australian Patent Office Nov 07 2016
Neptune Announces Stock Ticker Symbol Change to NEPT on the TSX Nov 04 2016
Acasti Announces Stock Ticker Symbol Change to ACST on the TSXV Nov 03 2016
Acasti Pharma Builds Intellectual Property Portfolio with Newly Issued U.S. Patent for CaPre Oct 26 2016
Neptune Technologies & Bioresources, Inc. :NEPT-US: Earnings Analysis: Q2, 2017 By the Numbers :... Oct 18 2016
Neptune Announces Q2 FY 2017 Results Oct 12 2016
Neptune Tech reports 2Q loss Oct 12 2016
Neptune Tech reports 2Q loss Oct 12 2016
Neptune Announces Second Quarter Results Oct 12 2016
Acasti Pharma Reports Second Quarter 2017 Financial Results Oct 11 2016
Neptune and Ingenutra Sign an Exclusive Worldwide Agreement for MaxSimil® Oct 07 2016
Here’s Why Aurinia Pharmaceuticals, Georgetown Bancorp, and Three Other Stocks Are on the Move... Oct 06 2016
Neptune and Aker BioMarine Reach Important Patent Agreement, Recognizing the Patents' Strength and... Oct 04 2016
Neptune and Aker BioMarine reach important patent agreement Oct 03 2016
Neptune to Hold Conference Call to Discuss Second Quarter Results FY2017 Sep 28 2016
Neptune to Hold Conference Call to Discuss Second Quarter Results for the Period Ended August 31,... Sep 28 2016
Neptune Introduces NKO Omega Plus Sep 15 2016
NEPTUNE Introduces NKO(R) Omega Plus, a New and Innovative Krill Oil Product with one of the Highest... Sep 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)